Alnylam Pharma (ALNY) Misses Q3 EPS by 15c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.72), $0.15 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $187.6 million versus the consensus estimate of $218.54 million.
2021 Financial Guidance
2021 Financial Guidance
Full year 2021 financial guidance is reiterated and consists of the following:
Combined net product revenues for |
| $640 million - $665 million |
Net revenues from collaborations and royalties |
| $150 million - $200 million |
GAAP R&D and SG&A expenses |
| $1,335 million - $1,455 million |
Non-GAAP R&D and SG&A expenses* |
| $1,175 million - $1,275 million |
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
